Biotech

Trillium Therapeutics Outlines Anticipated Activities and Milestones for 2017

TORONTO, ONTARIO: - Advancing the two ongoing clinical trials with TTI-621, an IgG1 SIRPaFc fusion protein targeting CD47; updated data anticipated in 2H/2017 - Expanding the CD47 franchise with TTI-622, an IgG4 SIRPaF ...

Invivoscribe Expands Long-Term Collaboration Agreement to Release FLT3 Mutation and Clonality Assay Kits

SAN DIEGO, CA: ...

Trillium Therapeutics Doses First Patient With TTI-621 in Phase 1 Solid Tumor Trial

TORONTO, ONTARIO: ...

Corcept Therapeutics Announces Preliminary Fourth Quarter and Full-Year 2016 Financial Results and Corporate Update; Provides 2017 Revenue Guidance

MENLO PARK, CA: ...

Calyx Provides Corporate Update

VANCOUVER, BRITISH COLUMBIA: ...

Cellestia Biotech AG: Cellestia Biotech raises CHF 8M seed financing

BASEL, SWITZERLAND: ...

Acquisition and Disposition of Securities of Hemostemix Inc.

CALGARY, ALBERTA: ...

Aldeyra Therapeutics Announces Clinical Development Update for Phase 3 Programs

LEXINGTON, MA: ...

Prima BioMed to Present at 2nd Annual Cancer Immunotherapy Conference

SYDNEY, AUSTRALIA: ...

Prima BioMed to Maintain NASDAQ Listing

SYDNEY, AUSTRALIA: ...